UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of ~~May~~June 2026

Commission File Number: 001-39822

Pharming Group N.V.

(Exact Name of Registrant as Specified in Its Charter)

Darwinweg 24

2333 CR Leiden

The Netherlands

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

~~INFORMATION~~Furnished ~~CONTAINED~~as INExhibit ~~THIS~~99.1 ~~REPORT~~to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated June 04, 2026.

Annual General Meeting of Shareholders

On May 28, 2026, Pharming Group N.V. (“Pharming” or the “Company”) issued a press release concerning the results of its Annual General Meeting of Shareholders (“AGM”) held today. The press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Auditor Change from Deloitte to KPMG

Deloitte Accountants B.V. (“Deloitte”) was previously reappointed as external auditor to the Company on June 11, 2025, for a one-year term.

On recommendation of the Audit Committee of the Board of Directors of the Company, the Board of Directors proposed to the AGM that the AGM appoint KPMG Accountants N.V. (“KPMG”) as external auditor for the financial years 2026, 2027 and 2028. The AGM approved such proposal, and KPMG was therefore so appointed on May 28, 2026.

Deloitte was dismissed on May 28, 2026, as external auditor to the Company.

The reports of Deloitte on the consolidated financial statements of the Company as of December 31, 2025 and 2024, and for each of the three years in the period ended December 31, 2025, contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

During the fiscal years ended December 31, 2025 and 2024, and the subsequent period through May 28, 2026, there were (i) no “disagreements” (as that term is defined in Item 16F(a)(1)(iv) of Form 20-F) between the Company and Deloitte on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Deloitte, would have caused Deloitte to make reference to the subject matter of the disagreement in Deloitte’s reports on the consolidated financial statements of the Company for such years, and (ii) no reportable events as defined in Item 16F(a)(1)(v) of Form 20-F, other than the material weaknesses in internal control over financial reporting disclosed in Item 15 of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024.

The Company provided Deloitte with a copy of the disclosures it is making in this report on Form 6-K and requested that Deloitte furnish it with a letter addressed to the U.S. Securities and Exchange Commission (the “SEC”) stating whether or not Deloitte agrees with the above disclosures and, if not, stating the respects in which Deloitte does not agree. A copy of Deloitte’s letter to the SEC, dated May 28, 2026, is furnished herewith as Exhibit 99.2 to this report on Form 6-K.

During the fiscal years ended December 31, 2025 and 2024, and the subsequent period through May 28, 2026, neither the Company nor anyone on its behalf consulted with KPMG regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, (ii) the type of audit opinion that might be rendered on the Company’s financial statements and neither a written report nor oral advice was provided to the Company that KPMG concluded was an important factor considered by the Company in reaching a decision as to accounting, auditing or financial reporting issues, (iii) any matter that was the subject of a disagreement (as defined in Item 16F(a)(1)(iv) of Form 20-F and the related instructions), or (iv) any reportable event (as described in Item 16F(a)(1)(v) of Form 20-F).

EXHIBIT INDEX

Exhibit No.						Description
99.1						Pharming ~~Group~~ announces ~~results~~U.S. ofFDA ~~2026~~acceptance ~~Annual~~ofsNDA ~~General~~resubmission ~~Meeting~~for ofJoenja® ~~Shareholders~~(leniolisib) to treatchildren aged 4 to 11 years with APDS
99.2						Letter from Predecessor Auditor

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Pharming Group N.V.

By:	/s/ Fabrice Chouraqui

	Name:	Fabrice Chouraqui
	Title:	CEO

Date: ~~May~~June 2804, 2026

~~Exhibit~~Pharming 99announces U.1S. FDA acceptance of

~~Pharming~~sNDA ~~Group~~resubmission ~~announces~~for ~~results~~Joenja® of(leniolisib) ~~2026~~to ~~Annual General Meeting of Shareholders~~ treat

~~Leiden,~~children ~~the~~aged ~~Netherlands,~~4 ~~May~~to ~~28,~~11 ~~2026:~~years ~~Pharming~~with Group (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held earlier today.APDS

~~KPMG~~•If ~~Accountants~~approved, ~~N.V.~~Joenja ~~was~~will ~~appointed~~be as the ~~Company’s~~first ~~independent~~approved ~~external~~treatment ~~auditor~~in ~~for~~ the ~~financial years 2026 through 2028 (agenda item 3)~~U.S. ~~Shareholders also approved the proposals to amend the Remuneration policy~~ for ~~the~~children ~~Board~~with ofactivated ~~Directors~~phosphoinositide ~~regarding the fees to be paid to the Non~~3-~~Executive~~kinase ~~Directors~~delta (~~agenda item 4~~PI3Kδ), tosyndrome ~~renew the authorizations for the Board of Directors to issue shares~~ (~~agenda item 5~~APDS), ~~and~~a torare ~~repurchase~~primary ~~shares~~immunodeficiency ~~(agenda item 6).~~

A•Supplemental ~~recording~~New ofDrug ~~the~~Application ~~webcast,~~(sNDA) ~~the~~resubmission ~~AGM~~seeks ~~presentation~~approval ~~slides,~~for ~~voting~~40 ~~results~~mg and ~~additional~~50 ~~information~~mg ontwice-daily ~~the agenda items are available on the Company’s website under Investors/Shareholder Meetings.~~ dosing

•Separate sNDA for lower weight pediatric patients planned for second half 2026

Leiden, the Netherlands, June 4, 2026: Pharming Group (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. Following the Complete Response Letter (CRL) received on January 30, 2026, and a subsequent Type A meeting with the FDA on March 26, 2026, the resubmission seeks approval of 40 mg and 50 mg twice-daily dosing for pediatric patients weighing 27 kg or more, who represent a meaningful proportion of the identified pediatric patient population. The resubmission includes additional data requested by the FDA on analytical methods used for production batch testing. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026.

A separate sNDA seeking approval for lower doses for patients weighing less than 27 kg is planned for this summer.

Fabrice Chouraqui, Chief Executive Officer of Pharming, commented:

“We are pleased that the FDA has accepted our resubmission, bringing us one step closer to potentially making Joenja available to younger patients living with APDS. These young patients and their families continue to face the significant burden of this rare disease, and there is a clear need for an approved targeted treatment. We look forward to the continued collaboration with the FDA to help bring Joenja to the broader pediatric APDS population as quickly as possible.”

The resubmission is supported by positive data from the open-label, multinational, single-arm Phase III study in children aged 4 to 11 years, which showed improvements over 12 weeks in two clinically relevant hallmarks of APDS, reduced lymphadenopathy and increased naïve B cells, together indicating a correction of the underlying immune defect. The improvements in lymphoproliferation and immunophenotype correction were seen across all dose levels investigated and were consistent with the improvements previously reported in adolescent and adult patients. All treatment emergent adverse events were reported to be mild to moderate in

nature. There were no drug related serious adverse events, and all patients completed the 12-week treatment period.

Joenja received approval from the FDA for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023.

About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS)

APDS is a rare primary immunodeficiency that was first characterized in 2013. APDS is caused by variants in either one of two identified genes known as PIK3CD or PIK3R1, which are vital to the development and function of immune cells in the body. Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway, which causes immune cells to fail to mature and function properly, leading to immunodeficiency and dysregulation.1,2,3 APDS is characterized by a variety of symptoms, including severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.4,5 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, it has been reported that people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.4-7 A definitive diagnosis can be made through genetic testing. APDS affects approximately 1 to 2 people per million worldwide.8

About leniolisib

Leniolisib is an oral small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor approved as the first and only targeted treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in the U.S., U.K., Australia and Israel in adult and pediatric patients 12 years of age and older and in Japan for patients 4 years of age and older. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate, which serves as an important cellular messenger and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Results from a randomized, placebo-controlled Phase III clinical trial demonstrated statistically significant improvement in the coprimary endpoints, reflecting a favorable impact on the immune dysregulation and deficiency seen in these patients, and open label extension data has supported the safety and tolerability of long-term leniolisib administration.9,10

Leniolisib is currently under regulatory review for the treatment of APDS in Canada and several other countries. Leniolisib is also being evaluated in two Phase II clinical trials in primary immunodeficiencies (PIDs) with immune dysregulation. The safety and efficacy of leniolisib has not been established for PIDs with immune dysregulation beyond APDS.

About Pharming Group N.V.

Pharming Group N.V. (~~Euronext~~EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations.

For more information, visit www.pharming.com and find us on LinkedIn.

Forward-looking Statements

This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2025 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

Inside Information

This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

References

1.Lucas CL, et al. Nat Immunol. 2014;15(1):88-97.

2.Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218.

3.Nunes-Santos C, Uzel G, Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687.

4.Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606.

5.Maccari ME, et al. Front Immunol. 2018;9:543.

6.Jamee M, et al. Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333.

7.Condliffe AM, Chandra A. Front Immunol. 2018;9:338.

8.Vanselow S, et al. Frontiers in Immunology. 2023;14:1208567.

9.Rao VK, et al Blood. 2023 Mar 2;141(9):971-983.

10.Rao VK, et al. J Allergy Clin Immunol 2024;153:265-74.

For further public information, contact:

Investor Relations

Michael Levitan, VP Investor Relations ~~and~~& Capital Markets

T: +1 (908) 705 1696

E: investor@pharming.com

Media Relations

Global: Saskia Mehring, Head of Corporate Communications

T: +31 6 28 32 60 41

E: media.relations@pharming.com

U.S.: Christina Skrivan (Precision AQ on behalf of Pharming)

T: +1 (636)-352-7883

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)

T: +31 6 53 81 64 27

Exhibit 99.2

May 28, 2026

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-7561

Dear Sirs/Madams:

We have read the Form 6-K of Pharming Group N.V. dated May 28, 2026, and have the following comments:

1.We agree with the statements made in paragraphs 1, 3, 4, 5, and 6 of the section titled “Auditor Change from Deloitte to KPMG”.

2.We have no basis on which to agree or disagree with the statements made in paragraphs 2, and 7 of the section titled “Auditor Change from Deloitte to KPMG”, and outside of the aforementioned section.

Yours truly,

/s/ Deloitte Accountants B.V.

Filing Compare · Pharming Group N.V.